Gastroenterology · Medical Literature
The Effect of a Probiotic on Gut Microbiota Stability and Systemic Well-Being during Short-Term Travel.
Abstract
Short-term travel, particularly to new environments, can disrupt gut microbiota homeostasis and induce a range of physical and psychological symptoms. While probiotics are proposed to mitigate these effects, evidence from well-controlled trials during domestic travel, especially along unique routes like China's Silk Road, remains limited. This study investigated the efficacy of a multi-strain Bifidobacterium probiotic in maintaining gut microbiota stability and alleviating travel-related symptoms. In a randomized, double-blind, placebo-controlled trial, 74 healthy adults traveling to Xinjiang were assigned to receive either a probiotic (n = 39; B. longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536, 1.5 × 109 CFU/day) or a placebo (n = 35) for five days during travel. Gut microbiota was profiled via metagenomic sequencing (pre- and post-travel), and symptoms were recorded daily. Primary outcomes were changes in gut microbiota composition and function (KEGG pathways). Secondary outcomes included respiratory, gastrointestinal, and systemic symptom scores. Data were analyzed on an intention-to-treat basis. While alpha and beta diversity remained stable in both groups, the probiotic group exhibited a distinct post-travel microbiota enriched with beneficial taxa, including Bifidobacterium breve and Intestinibacillus at the genus level, and Lacticaseibacillus rhamnosus, Lacticaseibacillus paracasei, and other Lacticaseibacillus species. qPCR confirmed significant increases in administered strains B. longum subsp. infantis (p < 0.001) and B. breve (p < 0.001). KEGG analysis revealed that the probiotic group maintained a metabolically focused profile (e.g., peptidoglycan biosynthesis, histidine metabolism), whereas the placebo group showed increased abundance of microbial pathways associated with host disease-related signaling (e.g., Huntington disease, various cancers) and inflammatory signaling (e.g., PI3K-Akt signaling pathway). Symptomatically, the probiotic group demonstrated a significantly greater reduction than the placebo in irritability (-92% vs. -31%; p = 0.033) and fatigue (-24% vs. +43%; p = 0.024) post-travel, and reported less dizziness (-100% vs. -35%; p = 0.024). Supplementation with a multi-strain Bifidobacterium probiotic during short-term travel promoted the colonization of beneficial bacteria, stabilized gut microbial function against travel-induced dysregulation, and may contribute to supporting systemic well-being during travel.
Clinical relevance
Short-term travel, even within a domestic setting, can disrupt gut microbiota homeostasis and precipitate a constellation of gastrointestinal, respiratory, and systemic symptoms that impair traveler well-being. This randomized, double-blind, placebo-controlled trial addresses a meaningful evidence gap by evaluating a multi-strain Bifidobacterium probiotic in a controlled travel cohort along a geographically and environmentally distinct route (China's Silk Road/Xinjiang), a population and setting largely unstudied in prior probiotic literature. Gastroenterologists and travel medicine specialists should take note as this study provides mechanistic (metagenomic and KEGG pathway) as well as symptomatic outcome data to support probiotic use in short-duration travel contexts.
Key findings
1. In a 74-participant RCT (probiotic n=39, placebo n=35), alpha and beta diversity indices remained stable in both arms post-travel, indicating that overall microbial richness and community structure were preserved regardless of intervention. 2. The probiotic group demonstrated a significantly enriched post-travel microbiota with beneficial taxa including Bifidobacterium breve and Intestinibacillus at the genus level, as well as Lacticaseibacillus rhamnosus and Lacticaseibacillus paracasei at the species level, compared to placebo. 3. qPCR confirmed successful engraftment of the administered strains, with significant post-travel increases in both B. longum subsp. infantis (p < 0.001) and B. breve (p < 0.001) in the probiotic group. 4. KEGG functional pathway analysis revealed that the probiotic group maintained a metabolically focused microbial profile (e.g., peptidoglycan biosynthesis, histidine metabolism), whereas the placebo group exhibited increased abundance of pathways linked to host disease-related and inflammatory signaling, including PI3K-Akt signaling, Huntington disease pathways, and various cancer-associated pathways. 5. The probiotic group demonstrated a significantly greater reduction in irritability compared to placebo (-92% vs. -31%; p = 0.033) and a favorable divergence in fatigue scores (-24% vs. +43%; p = 0.024) post-travel. 6. Dizziness was significantly less prevalent in the probiotic group versus placebo post-travel (-100% vs. -35%; p = 0.024), suggesting a systemic well-being benefit extending beyond the gastrointestinal tract.
Practice implications
Clinicians advising healthy adults undertaking short-term travel, particularly to environmentally novel destinations, may consider prophylactic supplementation with a multi-strain Bifidobacterium probiotic (specifically B. longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 at 1.5 × 10⁹ CFU/day) initiated at the onset of travel and continued for the duration (at least five days), based on demonstrated benefits in microbial stabilization and symptom reduction. The observed improvements in systemic symptoms—irritability, fatigue, and dizziness—suggest a gut-brain axis mechanism that broadens the clinical rationale for probiotic use beyond traditional gastrointestinal indications in the travel medicine setting. Given the intention-to-treat design and relatively small sample size, these findings should be considered hypothesis-generating; clinicians should await larger, multi-site trials before adopting this as standard prophylactic protocol, and should individualize recommendations based on patient immune status, baseline microbiota health, and destination-specific enteric risk.